5164 Federal Register / Vol. 74, No. 18 / Thursday, January 29, 2009 / Notices 

EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN—Continued 

Form Name Number of 

respondents 

Total burden 

hours 

Average 

hourly wage 

rate* 

Total cost 

burden 

Web site visitors survey ................................................................................... 150 30 30.33 910 

Total .......................................................................................................... 166 125 na 3,791

* The average hourly wage rate of $30.33 was calculated based on the following mean hourly wage rates: pharmacists—$47.58; pharmacy 

manager [medical & health services manager category]—$50.34; pharmacy tecimicians—$13.25; and pharmacy aides $10.15. The mean hourly 

wage rates for these occupations were obtained from the Bureau of Labor & Statistics on ‘‘Occupational Employment and Wages, May 2007,’’ 

found at: http//www.bls.gov/OES/current/oes291051.htm. 

Estimated Annual Costs to the 

Government 

The total cost of this contract to the 

government is $400,000. The project 

extends over three fiscal years. Exhibit 

3 shows a breakdown of the total cost 

as well as the annualized cost. 

EXHIBIT 3 

Cost component Total cost Annualized 

cost 

Project Development ............................................................................................................................................... $54,822 $18,274 

Data Collection Activities ......................................................................................................................................... 111,509 37,170 

Data Processing and Analysis ................................................................................................................................. 129,089 43,030 

Publication of Results .............................................................................................................................................. 63,736 21,245 

Project Management ................................................................................................................................................ 40,845 13,615 

Total .................................................................................................................................................................. 400,000 133,333 

Request for Comments 

In accordance with the above cited 

legislation, comments on the AHRQ 

information collection proposal are 

requested with regard to any of the 

following: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of functions 

of AHRQ, including whether the 

information will have practical utility; 

(b) the accuracy of AHRQ’s estimate of 

burden (including hours and costs) of 

the proposed collection of information; 

(c) ways to enhance the quality, utility, 

and clarity on the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including the use of 

automated collection techniques or 

other forms of information technology. 

Comments submitted in response to 

this notice will be summarized and 

included in the request for OMB 

approval of the proposed information 

collection. All comments will become a 

matter of public record. 

Dated: January 16, 2009. 

Carolyn M. Clancy, 

Director. 

[FR Doc. E9–1751 Filed 1–28–09; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: Protection and Advocacy (P&A) 

Voting Access Application and Annual 

Report. 

OMB No.: 0970–0326. 

Description: This is a revision to 

include the application for the 

previously cleared Help America Vote 

Act (HAVA) Annual report. 

An application is required by Federal 

statute (the Help America Vote Act 

(HAVA) of 2002, Pub. L. 107–252, 

Section 291, Payments for Protection 

and Advocacy Systems, 42 U.S.C. 

15461). Each State Protection & 

Advocacy (P&A) System must prepare 

an application in accordance with the 

program announcement. 

There is no application kit; the P&As 

application may be in the format of its 

choice. It must, however, be signed by 

the P&As Executive Director or the 

designated representative, and contain 

the assurances as outlined under Part I. 

C. Use of Funds. The P&As designated 

representatives may signify their 

agreement with the conditions/ 

assurances by signing and returning the 

assurance document Attachment B, 

found in Part IV of this Instruction. The 

assurance document signed by the 

Executive Director of the P&A, or other 

designated person, should be submitted 

with the application to the 

Administration on Developmental 

Disabilities. 

An annual report is required by 

Federal statute (the Help America Vote 

Act (HAVA) of 2002, Pub. L. 107–252, 

Section 291, Payments for Protection 

and Advocacy Systems, 42 U.S.C. 

15461). Each State Protection & 

Advocacy (P&A) System must prepare 

and submit an annual report at the end 

of every fiscal year. The report 

addresses the activities conducted with 

the funds provided during the year. The 

information from the annual report will 

be aggregated into an annual profile of 

how HAVA funds have been spent. The 

report will also provide an overview of 

the P&A goals and accomplishments 

and permit the Administration on 

Developmental Disabilities to track 

progress to monitor grant activities. 

Respondents: Protection & Advocacy 

Systems—All States, the District of 

Columbia, Puerto Rico, the U.S. Virgin 

Islands, American Samoa, and Guam. 


rmajette on PRODPC74 with NOTICES
Federal Register / Vol. 74, No. 18 / Thursday, January 29, 2009 / Notices 5165 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total burden 

hours 

Protection and Advocacy (P&A) Voting Access Application ........................... 55 1 20 1,100 

Protection and Advocacy (P&A) Voting Access Annual Report ...................... 55 1 16 880 

Estimated Total Annual Burden 

Hours: 1,980. 

Additional Information: Copies of the 

proposed collection may be obtained by 

writing to the Administration for 

Children and Families, Office of 

Administration, Office of Information 

Services, 370 L’Enfant Promenade, SW., 

Washington, DC 20447, Attn: ACF 

Reports Clearance Officer. All requests 

should be identified by the title of the 

information collection. E-mail address: 

infocollection@acf.hhs.gov. 

OMB Comment: OMB is required to 

make a decision concerning the 

collection of information between 30 

and 60 days after publication of this 

document in the Federal Register . 

Therefore, a comment is best assured of 

having its full effect if OMB receives it 

within 30 days of publication. Written 

comments and recommendations for the 

proposed information collection should 

be sent directly to the following: Office 

of Management and Budget, Paperwork 

Reduction Project, Fax: 202–395–6974, 

Attn: Desk Officer for the 

Administration for Children and 

Families. 

Dated: January 26, 2009. 

Janean Chambers, 

Reports Clearance Officer. 

[FR Doc. E9–1925 Filed 1–28–09; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Arthritis Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Arthritis 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on March 5, 2009, from 8:30 a.m. 

to 4:00 p.m. 

Location: Hilton Washington DC/ 

Silver Spring, The Ballrooms, 8727 

Colesville Rd., Silver Spring, MD. The 

hotel telephone number is 301–589– 

5200. 

Contact Person: Nicole Vesely, Center 

for Drug Evaluation and Research (HFD– 

21), Food and Drug Administration, 

5600 Fishers Lane (for express delivery, 

5630 Fishers Lane, rm. 1093), Rockville, 

MD 20857, 301–827–6793, fax: 301– 

827–6776, e-mail: 

nicole.vesely@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512532. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate committee 

hot line/phone line to learn about 

possible modifications before coming to 

the meeting. 

Agenda: The committee will discuss 

biologics license application (BLA) 

125293, pegloticase, Savient 

Pharmaceuticals, Inc., as a therapy for 

patients with treatment failure gout. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ohrms/ 

dockets/ac/acmenu.htm, click on the 

year 2009 and scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before February 19, 2009. 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. to 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or February 10, 2009. Time allotted for 

each presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by February 11, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Nicole 

Vesely at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/oc/advisory/ 

default.htm for procedures on public 

conduct during advisory committee 

meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C.app. 2). 

Dated: January 21, 2009. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E9–1820 Filed 1–28–09; 8:45 am] 

BILLING CODE 4160–01–S 


rmajette on PRODPC74 with NOTICES